Move Over, ChatGPT: Stock Picks For Leveraging The Power Of AI In Health Care, Cybersecurity
Move Over, ChatGPT: Stock Picks For Leveraging The Power Of AI In Health Care, Cybersecurity
Generative artificial intelligence has taken the world by storm in 2023.
生成人工智能在 2023 年席捲了全世界。
Programs like Open AI's ChatGPT, with the ability to write code and produce realistic writing in multiple styles, are bound to change the way humans interact with technology.
類似的程序 開放式 AI的 聊天室,具有編寫代碼並以多種樣式產生逼真寫作的能力,必然會改變人類與技術互動的方式。
Read also: ChatGPT Just Got Banned In Parts Of Europe, Isn't It Supposed To Be A Gold Rush?
另請閱讀:ChatGPT 剛剛在歐洲部分地區被禁止,不是應該是淘金熱嗎?
The Wider World Of AI: When Microsoft Corp (NASDAQ:MSFT) announced it would be including a version of ChatGPT to interact with users of its Bing search engine, investors began considering the Bill Gates-founded company as a worthy competitor of Alphabet Inc (NASDAQ:GOOG)'s Google in the dominance of web search.
更廣闊的世界 人工智能: 何時 微軟 公司 (納斯達克:MSFT) 宣布,它將包括一個版本的聊天 GPT 與其用戶進行交互 Bing 搜索引擎,投資者開始考慮 比尔·盖茨-成立公司作為一個值得競爭對手 字母 公司 (納斯達克:古格)'s 谷歌 在網絡搜索的統治地位。
Yet for all the fuss that generative AI programs like ChatGPT have caused over the past few months, other types of artificial intelligence are also gaining ground as potential value generators in the near future.
然而,對於像 ChatGPT 這樣的生成 AI 程序在過去幾個月中引起的所有大驚小怪,其他類型的人工智能也在不久的將來成為潛在的價值產生器。
According to The Street Sheet newsletter, AI's ability to interpret big data is at the forefront of this technology's disruptive potential. Industries where big data can be leveraged are the most likely to become affected.
根據街頭報導,AI 解讀大數據的能力是這項技術顛覆性潛力的最前沿。可以利用大數據的行業最有可能受到影響。
In the health care sector, AI can be used to speed up drug discovery in a process called in-silico, which precedes in-vitro, animal and human trials. Companies in the psychedelics space, for instance, have been looking at in-silico drug discovery for years, using AI-assisted tools to come up with thousands of new drug candidates at a time.
在醫療保健領域,人工智能可用於在體外,動物和人體試驗之前的一種稱為 silico 的過程中加快藥物發現速度。例如,迷幻藥領域的公司多年來一直在研究 insilico 藥物發現,使用人工智能輔助工具一次提出成千上萬的新候選藥物。
AI could also be leveraged to create precision drugs based on a patient's particular genome.
人工智能也可以根據患者的特定基因組來製造精密藥物。
The Street Sheet shared stock picks for investors searching to gain exposure to AI in the health care market, where it said these ETFs provide the best risk-reward ratio:
街頭報告為尋求在醫療保健市場接觸人工智能的投資者分享了股票精選,並表示這些 ETF 提供了最佳的風險回報比率:
- The iShares Genomics Immunology and Healthcare ETF (NYSE:IDNA), which has $140 million in assets under management and an expense ratio of just 0.47%.
- The ARK Genomic Revolution ETF (BATS:ARKG), with around $2 billion in assets under management and an expense ratio of 0.75%.
- 該 安碩基因體免疫及醫療保健 ETF 紐約證交所代號:IDNA),其管理資產達 1.4 億美元,支出比率僅為 0.47%。
- 該 方舟基因組革命 ETF 管理資產約為 20 億美元,支出比率為 0.75%。
Another industry that can greatly benefit from AI's ability to rapidly handle large data sets is cybersecurity. One way in which AI can be leveraged in this field is to predict when and where cyberattacks are going to occur.
另一個可以從 AI 快速處理大型數據集的能力中獲益的行業是網絡安全。在此領域中可以利用 AI 的一種方法是預測何時何地發生網絡攻擊。
ETFs that can provide exposure to this application of AI technology are:
可以提供這種 AI 技術應用敞口的 ETF 是:
- The iShares Cybersecurity & Tech ETF (NYSE:IHAK)
- The ETFMG Prime Cyber Security ETF (NYSE:HACK)
- The Global X Cybersecurity ETF (NASDAQ:BUG)
- 該 安碩網絡安全及科技 ETF (紐約證交所:阿哈克)
- 該 ETFMG 主要網絡安全 ETF (新聞:駭客)
- 該 全球 X 網絡安全 ETF(納斯達克:缺陷)
Photo by Alex Knight on Unsplash.
照片由亞歷克斯·奈特在未飛濺。